Genentech, Inc.

Plexxikon Inc.

F. Hoffmann-la Roche Ag

Weiru Wang

Prabha N Ibrahim

Bryan K Chan

Jun Liang

Chao Zhang

Dean R Artis

Lewis J Gazzard

Robert A Lazarus

Jack Lin

Timothy Heffron

Yingnan Zhang

Rohan V Mendonca

Joy Drobnick

John Tellis

BinQing Wei

Michael Siu

Michael V Milburn

Clarence R Hurt

Heike I Krupka

James Arnold

Yan Wu

Andrew Madin

Eileen Mary Seward

Ryan Jefferson Watts

Sushant Malhotra

Emanuela Gancia

Michael Lainchbury

Craig Stivala

Kin Chiu Fong

Aihe Zhou

Naomi S Rajapaksa

Yonghan Hu

Jasvinder Atwal

Yongmei Chen

Cecilia Pui Chi Chiu

Matthew W Cartwright

David Favor

Andrew Good

Graham Elgin Jones

Aijun Lu

Baihua Hu

Blake Daniels

Malcolm Huestis

Edna F Choo

Huifen Chen

Shumei Wang

Daniel J Burdick

Binqing Wei

Shenghua Shi

Rebecca Zuckerman

Byunghun Lee

Naomi Rajapaksa

3-Carbonylaminoisoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the 3-carbonylaminoisoquinoline compounds.

Isoquinoline compounds for the treatment of cancer

3-Carbonylamino-8-aminoisoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the 3-carbonylamino-8-aminoisoquinoline compounds.

8-aminoisoquinoline compounds and uses thereof

Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.

Isoquinolines as inhibitors of HPK1

Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.

Naphthyridines as inhibitors of HPK1

The invention provides antibodies to specific neural proteins and methods of using the same.

Nucleic acid molecules encoding for BACE1 antibodies

The invention provides peptide inhibitors of BACE1 that bind to the active site in a noncanonical fashion, and methods of use thereof.

Peptide inhibitors of BACE1

Methods and compositions for neural disease immunotherapy

Compounds having the formula I wherein Rand Rare as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders. 

Substituted pyrrolo[2,3-b]pyrazines as serine/threonine kinase inhibitors

BACE1 antibodies

Compounds are described that are active on PPARs, including pan-active compounds. Also described are methods for developing or identifying compounds having a desired selectivity profile.

PPAR active compounds

Compounds are described that are active on at least one of PPAR&#x3b1;, PPAR&#x3b4;, and PPAR&#x3b3;, which are useful for therapeutic and/or prophylactic methods involving modulation of at least one of PPAR&#x3b1;, PPAR&#x3b4;, and PPAR&#x3b3;, wherein the compounds have the formula: wherein:

Growing community of inventors

Lafayette, CA, United States of America

Weiru Wang